A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer

Biotherapy

Volumn 9, Issue 1-3, 1996, Pages 123-132

  Pizza, Giancarlo ^a,b   De Vinci, Caterina ^a   Cuzzocrea, Diego ^b   Menniti, Domenico ^a   Aiello, Ernesto ^a   Maver, Paolo ^c   Corrado, Giuseppe ^a   Romagnoli, Piero ^a   Dragoni, Ennio ^a   Loconte, Giuseppe ^a   Riolo, Umberto ^a   Palareti, Aldopaolo ^a   Zucchelli, Paolo ^a   Fornarolai, Vittorio ^a   Viza, Dimitri ^a  

^a Immunodiagnosis and Immunotherapy Unit   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

cancer; cell mediated immunity; prostate; transfer factor; tumour associated antigens

Indexed keywords

TRANSFER FACTOR; TUMOR ANTIGEN;

ADULT; AGED; BLADDER; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOCYTE MIGRATION; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REMISSION; SURVIVAL RATE;

EID: 0029769040     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02628669     Document Type: Conference Paper

References (37)

1. Vanky F & Klein E. Specificity of auto-tumour cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int J Cane 1982: 29; 547-53.
2. Ting C & Yang SS. Effect of interleukin-2 in cytotoxic effectors. I. Short-term culture of the cytotoxic effectors and the in vivo anti-tumour activity of the cultured effectors isolated from tumour site. Int J Cane 1982; 30:625-32.
3. Vose BM &, Bonnard GD. Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in Interleukin-2. Int J Cane 1982; 29: 33-39.
4. Pizza G, Severini G, Menniti D, De Vinci C & Corrado F. Tumour regression after intralesional injection of interleukin2 (IL-2) in bladder cancer. Preliminary report. Int J Cane 1984; 34: 359-67.
5. Lawrence HS: Transfer Factor in cellular immunity. Harvey Lecture Series 68. New York: Academic Press, 1974: 75-89.
6. Spitler LE: BCG, levamisole and transfer factor in the treatment of cancer. Prog Ex Turn 1978; 25:178-88.
7. Bukowski RM, Deodhar S & Hewlett J. Immunotherapy of human neoplasms with transfer factor. In: Ascher MS, Gottlieb AA & Kirkpatrick CH, eds. Transfer factor: basic properties and clinical applications. New York: Academic Press, 1976: 543-51.
8. Levin AS, Byers VS, LeCam L & Johnston JO. An unusual metastatic lesion in a patient with osteosarcoma receiving tumour specific transfer factor. In: Ascher MS, Gottlieb AA & Kirkpatrick CH, eds. Transfer factor: basic properties and clinical applications. New York: Academic Press, 1976: 537-43.
9. Bearden JD, Thor DE & Coltman CA. Adjunctive transfer factor in osteogenic sarcoma. I. Clinical implications of chemotherapy and immunotherapy. In: Ascher MS, Gottlieb AA & Kirkpatrick CH, eds. Transfer factor: basic properties and clinical applications. New York: Academic Press, 1976: 553-62.
10. Gutterman JU, Mavligit G, Reed R, Richman S, McBride CE & Hersh EM. Immunology and immunotherapy of humanmalignant melanoma: historic review and perspectives for the future. Semin Oncol 1975; 2(2): 155.
11. Pizza G, De Vinci C & Fudenberg HH. Transfer factor in malignancy. Prog Drug Res 1993; 42; 401-21.
12. Levin AS, Byers VS, Fudenberg HH, Wybran J, Johnston JO & Hackett AJ. Osteogenic sarcoma: immunologie parameters before and during immunotherapy with tumour specific transfer factor. J Clin Inv 1975; 55: 487-97.
13. Byers VS, Levin AS, LeCam L, Johnston JO & Hackett AJ. Discussion paper: tumor-specific transfer factor therapy in osteogenic sarcoma: a two-year study. Ann NY Acad Sei 1976; 277: 621-27.
14. Pizza G, Viza D, Boucheix C & Corrado F. In vitro production of a transfer factor specific for transitional-cell carcinoma of the bladder. Br J Cane 1976; 33: 606-11.
15. Pizza G, Viza D, Boucheix D & Corrado F. Studies with in vitro produced transfer factor. In: Ascher MS, Gottlieb AA & Kirkpatrick CH, eds. Transfer factor: basic properties and clinical applications. New York: Academic Press, 1976: 17384.
16. Pizza G, Viza D , Boucheix C & Corrado F. Effect of in vitro produced transfer factor on the immune response of cancer patients Eur J Cane 1977; 13(9): 917-23.
17. Krown SE, Pinsky CM, Hirshaut Y, Hansen JA & Oettgen HF. Effects of transfer factor in patients with advanced cancer. Isr J Med S 1978; 14(10): 1026-38.
18. Busutti L, Blotta A, Mastrorilli M, Savorani G, Pizza G & De Vinci C. Transfer factor adjuvant therapy in nonsmall- cell lung carcinoma. (NSCLC) after surgery and radiotherapy. J Exp Path 1987; 3(4): 565-68.
19. Kirsh MM, Orringer MB, McAuliffe S, Schork MA, Katz B & Suva J. Transfer factor in the treatment of carcinoma of the lung. Ann Thorac 1984; 38: 140-45.
20. Fujisawa T, Yamaguchi Y, Kimura H, Arita M, Baba M & Shiba M. Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer 1984; 54: 663-69
21. Fujisawa T, Yamaguchi Y, Kimura K, Arita M, Shiba M & Baba M. Randomized controlled trial of transfer factor irnmunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn J Surg 1984; 14(6): 452-58
22. Fujisawa T, Yamaguchi Y & Kimura H. Transfer factor in restoration of cell mediated immunity in lung cancer patients. Jpn J Surg 1983; 13(4), 304-11.
23. Whyte RI, Schork MA, Sloan H, Orringer MB & Kirsh MM. Adjuvant treatment using transfer factor forbronchogenic carcinoma: long-term follow-up. Ann Thorac 1992; 53(3): 39196.
24. Pilota V, Mastrorilli M, Pizza G, DeVinci C, Busutti L, Palareti A, Gozzetti G & Cavallari A. The Impact of transfer factor in adjuvant NSC lung cancer therapy. Biotherapy: this issue.
25. Shaw MW, Ablin RJ, Guinan PD & Bhatti RA. Effect of transfer factor on tumor-associated immunity and tumor growth of the Dunning R-3327G rat prostate adenocarcinoma Am J Reprod Immunol Microbiol 1985; 3: 80-83.
26. Corrado F, Pizza G, De Vinci C & Corrado G. Il trattamento con Transfer Factor delle metastasi ossee da adenocarcinoma della prostata. In: Saccani F., Becchi G, Carretti D, Maltoni C, eds. Le Metastasi. Bologna: Monduzzi Editore, 1986; 123335.
27. Corrado F, Pizza G, De Vinci C, Corrado G, Mannini D, Maver P, Fern C & Aiello E. L'impiego del Transfer Factor nel carcinoma prostatico metastatizzato. In: Garofalo F, TomaselU V Eds. Atti del Convegno Internazionale sul Cancro della Prostata. Bologna: Monduzzi Editore, 1988; 89-92.
28. Corrado F & Pizza G. Tentativas de inmunoterapia en los tumores del aparato urinario. Arch Esp Urol 1984; 37 Suppi. 2: 659-66.
29. Corrado F, Pizza G, De Vinci C, Fern C, Mannini D, Corrado G & Maver P. Clinical and experimental immunotherapy of urological tumours: summary of experience. In: De Kernion JB ed. Immunotherapy of Urological Tumours. New York: Churchill Livingstone 1990; 335-37.
30. Murphy GP, Beckley S, Brady MF, Chu T, De Kernion JB, Dhabuwala C, Gaeta J, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmdt JD, Scott WW, Slack NH & Soloway MS. Treatment of newly diagnosed metatstatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983; 51: 1264-72.
31. Slack NH & Brady MF. Murphy and Investigators in the National Prostatic Cancer Project. The Prostate 1984; 5: 40115.
32. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985; 3: 1013-21.
33. Eisenberger MA, Simon RO & O'Dwyer PJ. A réévaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma, J Clin Oncol, 1985; 3: 827-41.
34. Ross CE, Cochran AJ, Hoyle DE, Grant RM & Mackie RM. Formalin-fixed tumour cells in the leukocytes migration test. Lancet 1973; ii, 1087.
35. Viza D, Boucheix Cl, Cesarini JP, Ablashi DV, Armstrong G, Levine P & Pizza G. Characterization of a human lymphoblastoid cell line, LDW7, used to replicate transfer factor and immune RNA. Bio. Cell 1982; 46: 1-10.
36. Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A & Miiller-Bérat N. 'In vitro' production of transfer factor by lymphoblastoid cell lines. Transplan P 1975; VII (suppl. 1): 329-33.
37. Oliver RTD: New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy. Eur J Cane 1995; 6: 859-60.